Elvin Dominic de Araujo

Elvin Dominic de Araujo

Auto-generated profile, based on publicly available information

Elvin Dominic de Araujo

Department of Chemical and Physical Sciences University of Toronto Mississauga Mississauga Ontario Canada

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2022 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
FEFettah Erdogan
Fettah Erdogan
TRTudor Bogdan Radu
Tudor Bogdan Radu
AOAnna Orlova
Anna Orlova
AQAbdul Khawazak Qadree
Abdul Khawazak Qadree
EAElvin Dominic de Araujo
Elvin Dominic de Araujo
PGPatrick Gunning
Patrick Gunning
Through a comprehensive review and in silico analysis of reported data on STAT‐linked diseases, we analysed the communication pathways and interactome of the seven STATs in major cancer categories and proposed rational targeting approaches for therapeutic intervention to disrupt critical pathways and addictions to hyperactive JAK/STAT in neoplastic states. Although all STATs follow a similar molecular activation pathway, STAT1, STAT2, STAT4 and STAT6 exert specific biological profiles associated with a more restricted pattern of activation by cytokines. STAT3 and STAT5A as well as STAT5B have pleiotropic roles in the body and can act as critical oncogenes that promote many processes involved in cancer development. STAT1, STAT3 and STAT5 also possess tumour suppressive action in certain mutational and cancer type context. Here, we demonstrated member‐specific STAT activity in major cancer types. Through systems biology approaches, we found surprising roles for EGFR family members, sex steroid hormone receptor ESR1 interplay with oncogenic STAT function and proposed new drug targeting approaches of oncogenic STAT pathway addiction.

7 June 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
EAElvin D. de Araujo
Elvin D. de Araujo
FEFettah Erdogan
Fettah Erdogan
HNHeidi Neubauer
Heidi Neubauer
DMDeniz Meneksedag-Erol
Deniz Meneksedag-Erol
PMPimyupa Manaswiyoungkul
Pimyupa Manaswiyoungkul
PGPatrick Gunning
Patrick Gunning
Hyper-activated STAT5B variants are high value oncology targets for pharmacologic intervention. STAT5BN642H, a frequently-occurring oncogenic driver mutation, promotes aggressive T-cell leukemia/lymphoma in patient carriers, although the molecular origins remain unclear. Herein, we emphasize the aggressive nature of STAT5BN642H in driving T-cell neoplasia upon hematopoietic expression in transgenic mice, revealing evidence of multiple T-cell subset organ infiltration. Notably, we demonstrate STAT5BN642H-driven transformation of γδ T-cells in in vivo syngeneic transplant models, comparable to STAT5BN642H patient γδ T-cell entities. Importantly, we present human STAT5B and STAT5BN642H crystal structures, which propose alternative mutation-mediated SH2 domain conformations. Our biophysical data suggests STAT5BN642H can adopt a hyper-activated and hyper-inactivated state with resistance to dephosphorylation. MD simulations support sustained interchain cross-domain interactions in STAT5BN642H, conferring kinetic stability to the mutant anti-parallel dimer. This study provides a molecular explanation for the STAT5BN642H activating potential, and insights into pre-clinical models for targeted intervention of hyper-activated STAT5B.

7 November 2022 in EMBO Molecular Medicine
Verified
Journal Article
Open access
HSHelena Sorger
Helena Sorger
SDSaptaswa Dey
Saptaswa Dey
PVPablo Augusto Vieyra‐Garcia
Pablo Augusto Vieyra‐Garcia
DPDaniel Pölöske
Daniel Pölöske
ATAndrea R. Teufelberger
Andrea R. Teufelberger
PWPeter Wolf
Peter Wolf
Leukemic cutaneous T‐cell lymphomas (L‐CTCL) are lymphoproliferative disorders of skin‐homing mature T‐cells causing severe symptoms and high mortality through chronic inflammation, tissue destruction, and serious infections. Despite numerous genomic sequencing efforts, recurrent driver mutations have not been identified, but chromosomal losses and gains are frequent and dominant. We integrated genomic landscape analyses with innovative pharmacologic interference studies to identify key vulnerable nodes in L‐CTCL. We detected copy number gains of loci containing the STAT3/5 oncogenes in 74% (n = 17/23) of L‐CTCL, which correlated with the increased clonal T‐cell count in the blood. Dual inhibition of STAT3/5 using small‐molecule degraders and multi‐kinase blockers abolished L‐CTCL cell growth in vitro and ex vivo, whereby PAK kinase inhibition was specifically selective for L‐CTCL patient cells carrying STAT3/5 gains. Importantly, the PAK inhibitor FRAx597 demonstrated encouraging anti‐leukemic activity in vivo by inhibiting tumor growth and disease dissemination in intradermally xenografted mice. We conclude that STAT3/5 and PAK kinase interaction represents a new therapeutic node to be further explored in L‐CTCL.

31 August 2023 in Exploration of Targeted Anti-tumor Therapy
Verified
Journal Article
Open access
PDF file
DADiaaeldin I. Abdallah
Diaaeldin I. Abdallah
EAElvin D. de Araujo
Elvin D. de Araujo
NPNaman H. Patel
Naman H. Patel
LHLina S. Hasan
Lina S. Hasan
RMRichard Moriggl
Richard Moriggl
PGPatrick Gunning
Patrick Gunning
Histone deacetylases (HDACs) are a class of zinc (Zn)-dependent metalloenzymes that are responsible for epigenetic modifications. HDACs are largely associated with histone proteins that regulate gene expression at the DNA level. This tight regulation is controlled by acetylation [via histone acetyl transferases (HATs)] and deacetylation (via HDACs) of histone and non-histone proteins that alter the coiling state of DNA, thus impacting gene expression as a downstream effect. For the last two decades, HDACs have been studied extensively and indicated in a range of diseases where HDAC dysregulation has been strongly correlated with disease emergence and progression—most prominently, cancer, neurodegenerative diseases, HIV, and inflammatory diseases. The involvement of HDACs as regulators in these biochemical pathways established them as an attractive therapeutic target. This review summarizes the drug development efforts exerted to create HDAC inhibitors (HDACis), specifically class I HDACs, with a focus on the medicinal chemistry, structural design, and pharmacology aspects of these inhibitors.

16 June 2011 in Photosynthesis Research
Verified
Journal Article
Closed access
PDF file
EAElvin D. de Araujo
Elvin D. de Araujo
JPJason Patel
Jason Patel
CACharlotte de Araujo
Charlotte de Araujo
SRSusan P. Rogers
Susan P. Rogers
SSSteven Short
Steven Short
GEGeorge S. Espie
George S. Espie

31 July 2024 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
Peter Ábrányi-BaloghPeter Ábrányi-Balogh
Peter Ábrányi-Balogh
DBDávid Bajusz
Dávid Bajusz
ZOZoltán Orgován
Zoltán Orgován
AKAaron B. Keeley
Aaron B. Keeley
LPLászló Petri
László Petri
György M KeserűGyörgy M Keserű
György M Keserű
Fragment screening is a popular strategy of generating viable chemical starting points especially for challenging targets. Although fragments provide a better coverage of chemical space and they have typically higher chance of binding, their weak affinity necessitates highly sensitive biophysical assays. Here, we introduce a screening concept that combines evolutionary optimized fragment pharmacophores with the use of a photoaffinity handle that enables high hit rates by LC-MS-based detection. The sensitivity of our screening protocol was further improved by a target-conjugated photocatalyst. We have designed, synthesized, and screened 100 diazirine-tagged fragments against three benchmark and three therapeutically relevant protein targets of different tractability. Our therapeutic targets included a conventional enzyme, the first bromodomain of BRD4, a protein-protein interaction represented by the oncogenic KRasG12D protein, and the yet unliganded N-terminal domain of the STAT5B transcription factor. We have discovered several fragment hits against all three targets and identified their binding sites via enzymatic digestion, structural studies and modeling. Our results revealed that this protocol outperforms screening traditional fully functionalized and photoaffinity fragments in better exploration of the available binding sites and higher hit rates observed for even difficult targets.